India's first indigenous Covid-19 vaccine, Covaxin, is effective against multiple variants of the Covid-causing SARS-CoV-2 virus, including the double mutant strain found in India, according to a study by the Indian Council of Medical Research (ICMR).
The Covaxin, which has been developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR, is one of the two vaccines, the other being the Serum Institute of India's Covishield, that are currenly being used in India's Covid-19 vaccination drive.
According to the ICMR, the Pune-based National Institute of Virology (NIV) had successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus including the variants originating from United Kingdom, South Africa and Brazil.
The NIV has demonstrated the neutralization potential of the Covaxin against the variants from Brazil and UK in a study published in Journal of Travel Medicine in March.
Recently, the NIV successfully isolated and cultured the double mutant strain of the Coronavirus, identified in the certain regions of India and several other countries.
In the latest study, the Covaxin has been found to effectively neutralise the double mutant strain as well, according to the ICMR.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.